openPR Logo
Press release

Global Uterine Fibroids Treatment Devices Market to grow at a CAGR of 8.57% by 2032, Evaluates DelveInsight

10-09-2025 01:24 PM CET | Health & Medicine

Press release from: DelveInsight Business Research

Global Uterine Fibroids Treatment Devices Market to grow at

According to DelveInsight's analysis, The growth in demand for Uterine Fibroids Treatment Devices is largely driven by the rising prevalence The demand for uterine fibroids treatment devices is rising due to the growing prevalence of uterine fibroids, especially among women of reproductive age, creating a strong need for effective therapies. Increased awareness of the condition and improved healthcare access are facilitating earlier diagnoses, enabling timely interventions. Technological innovations have led to the development of minimally invasive and more efficient treatment devices, improving patient outcomes and shortening recovery periods. Additionally, key uterine fibroids treatment device manufacturers are investing in new product development, launching advanced ablation systems and robotic-assisted surgical tools. Together, these factors are expected to drive market growth from 2025 to 2032.

DelveInsight's "Uterine Fibroids Treatment Devices Market Insights, Competitive Landscape and Market Forecast-2032" report provides the current and forecast market outlook, forthcoming device innovation, challenges, market drivers and barriers. The report also covers the major emerging products and key Uterine Fibroids Treatment Devices companies actively working in the market.

To know more about why North America is leading the market growth in the Uterine Fibroids Treatment Devices market, get a snapshot of the report Uterine Fibroids Treatment Devices Market Trends
http://delveinsight.com/sample-request/uterine-fibroids-treatment-device-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Uterine Fibroids Treatment Devices Overview
Uterine fibroids treatment devices are medical tools or equipment designed to manage or remove uterine fibroids-noncancerous growths in the uterus. These devices include minimally invasive technologies such as uterine artery embolization (UAE) systems, radiofrequency ablation (RFA) devices, focused ultrasound (FUS) systems, and hysteroscopic surgical tools. They aim to reduce fibroid size, alleviate symptoms like heavy menstrual bleeding and pelvic pain, and preserve uterine function, offering alternatives to traditional surgical procedures such as hysterectomy or myomectomy.

DelveInsight Analysis: The worldwide market for uterine fibroids treatment devices is projected to expand at a CAGR of 8.57% over the forecast period from 2025 to 2032.

Uterine Fibroids Treatment Devices Market Insights
Geographically, North America is anticipated to hold the largest share of the Uterine Fibroids Treatment Devices market, driven by the growing prevalence of chronic diseases, ongoing research and development activities, supportive government initiatives aimed at raising awareness of chronic conditions, and increased healthcare spending, all of which are expected to significantly contribute to market growth during the forecast period.

To read more about the latest highlights related to Uterine Fibroids Treatment Devices, get a snapshot of the key highlights entailed in the Uterine Fibroids Treatment Devices
https://www.delveinsight.com/report-store/uterine-fibroids-treatment-device-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Recent Developments in the Uterine Fibroids Treatment Devices Market Report
• In January 2025, Hologic, Inc. finalized its acquisition of Gynesonics, Inc., acquiring the Sonata System. This cutting-edge technology integrates real-time intrauterine ultrasound with targeted radiofrequency ablation, offering a minimally invasive, incision-free transcervical treatment for symptomatic uterine fibroids, including cases associated with heavy menstrual bleeding.
• In October 2024,Caldera Medical acquired UVision 360, Inc., the developer of LUMINELLE® hysteroscopy and cystoscopy systems. This strategic move strengthens Caldera Medical's portfolio of minimally invasive solutions, particularly in advanced hysteroscopy, broadening its capabilities for diagnosing and treating intrauterine conditions like polyps, fibroids, and other related pathologies.
• In May 2024, Meditrina, a prominent company in women's health medical devices, obtained FDA 510(k) clearance for its Gen 2 bipolar RF hysteroscopy system. This innovative system utilizes bipolar radiofrequency technology and features the new Aveta Glo device, representing a notable advancement in minimally invasive gynecologic treatments.
• Thus, owing to such developments in the market, rapid growth will be observed in the Uterine Fibroids Treatment Devices market during the forecast period

Key Players in the Uterine Fibroids Treatment Devices Market
Some of the key market players operating in the Uterine Fibroids Treatment Devices market include- Hologic, Inc., Merit Medical Systems, Insightec, Boston Scientific Corporation, Profound Medical, Olympus Corporation, Medtronic, Intuitive Surgical, KARL STORZ, Cook, The Cooper Companies Inc., Terumo Corporation, Stryker, CONMED Corporation, Minerva Surgical, Inc., Smith+Nephew, Momentis Innovative Surgery, Asensus Surgical US, Inc., Koninklijke Philips N.V., Johnson & Johnson Services, Inc., and others.

Which MedTech key players in the Uterine Fibroids Treatment Devices market are set to emerge as the trendsetter explore @ Key Uterine Fibroids Treatment Devices Companies
http://delveinsight.com/sample-request/uterine-fibroids-treatment-device-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Analysis on the Uterine Fibroids Treatment Devices Market Landscape
Moreover, innovations in product development by leading Uterine Fibroids Treatment Devices companies are driving further growth in the market. For example, in September 2024, Gynesonics Inc., a company focused on minimally invasive solutions for symptomatic uterine fibroids, launched its SMART OS 2.4 software for the Sonata System. This system delivers an incision-free, uterus-preserving, transcervical treatment for symptomatic fibroids, offering patients a less invasive and highly effective alternative to conventional surgery. Such technological progress is contributing significantly to the expansion of the Uterine Fibroids Treatment Devices market.

Scope of the Uterine Fibroids Treatment Devices Market Report
• Coverage: Global
• Study Period: 2022-2032
• Uterine Fibroids Treatment Devices Market Segmentation By Product Type: Instruments and Consumables
• Uterine Fibroids Treatment Devices Market Segmentation By Procedure: Invasive, and Minimally Invasive {Laparoscopic Radiofrequency Ablation, Ultrasound Radiofrequency Ablation, Robotic-assisted Surgery, and Others
• Uterine Fibroids Treatment Devices Market Segmentation By End User: Hospitals, Ambulatory Surgical Centers, and others
• Uterine Fibroids Treatment Devices Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of the World
• Key Uterine Fibroids Treatment Devices Companies: Hologic, Inc., Merit Medical Systems, Insightec, Boston Scientific Corporation, Profound Medical, Olympus Corporation, Medtronic, Intuitive Surgical, KARL STORZ, Cook, The Cooper Companies Inc., Terumo Corporation, Stryker, CONMED Corporation, Minerva Surgical, Inc., Smith+Nephew, Momentis Innovative Surgery, Asensus Surgical US, Inc., Koninklijke Philips N.V., Johnson & Johnson Services, Inc., and others
• Porter's Five Forces Analysis, Product Profiles, Case Studies, KOL's Views, Analyst's View

Interested in knowing how the Uterine Fibroids Treatment Devices market will grow by 2032? Click to get a snapshot of the Uterine Fibroids Treatment Devices Market Analysis
http://delveinsight.com/sample-request/uterine-fibroids-treatment-device-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Contact Us
Gaurav Bora
info@delveinsight.com
+14699457679
www.delveinsight.com

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Global Uterine Fibroids Treatment Devices Market to grow at a CAGR of 8.57% by 2032, Evaluates DelveInsight here

News-ID: 4216073 • Views:

More Releases from DelveInsight Business Research

Global Artificial Intelligence In Diagnostics Market to grow at a CAGR of 11.16% by 2032, Evaluates DelveInsight
Global Artificial Intelligence In Diagnostics Market to grow at a CAGR of 11.16% …
According to DelveInsight's analysis, The increasing prevalence of cancer is driving the need for advanced diagnostic solutions, making Artificial Intelligence (AI) an essential tool for early detection and precision oncology. By integrating AI with medical imaging techniques like CT scans, MRIs, mammograms, and pathology slides, diagnostic accuracy is significantly enhanced, human errors are reduced, and cancer detection is accelerated, ultimately leading to improved patient outcomes. DelveInsight's "Artificial Intelligence In Diagnostics Market
Global Artificial Intelligence In Clinical Trials Market to grow at a CAGR of 12.04% by 2032, Evaluates DelveInsight
Global Artificial Intelligence In Clinical Trials Market to grow at a CAGR of 12 …
According to DelveInsight's analysis, The demand for AI in clinical trials is experiencing strong growth, primarily fueled by the rising global prevalence of chronic diseases, including diabetes, cardiovascular disorders, respiratory conditions, and cancer. This growth is further bolstered by increasing investments and funding dedicated to enhancing drug discovery and development processes. Additionally, the expanding trend of strategic partnerships and collaborations among pharmaceutical, biotechnology, and medical device companies is accelerating the
Human Papillomavirus Associated Cancer Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight
Human Papillomavirus Associated Cancer Pipeline 2025: Therapies, MOA Insights, a …
Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, Human Papillomavirus Associated Cancer pipeline constitutes key companies continuously working towards developing Human Papillomavirus Associated Cancer treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. "Human Papillomavirus Associated Cancer Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Human
Insulin Resistance Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight
Insulin Resistance Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clinical Tri …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Insulin Resistance pipeline constitutes 8+ key companies continuously working towards developing 10+ Insulin Resistance treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. "Insulin Resistance Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Insulin Resistance Market. The Insulin

All 5 Releases


More Releases for Uterine

Uterine Fibroids Symptoms
USA Fibroids Center is here to offer detailed information on https://www.usafibroidcenters.com/blog/uterine-fibroids-symptoms/ and help you discuss the best treatments for uterine fibroids at the clinic. Find out the best Fibroid Treatment for you! Treatments for uterine fibroids are accessed in women with problems related to them and show symptoms such as heavy menstrual bleeding, pain or pressure in the pelvis, or infertility and sterility.
Bharath Hospital Kottayam Offers Minimally Invasive Treatment for Uterine Fibroi …
Bharath Hospital Kottayam is excited introduce the latest advancement in women's healthcare - the Uterine Fibroid Embolization (UFE) treatment. Uterine fibroids are non-cancerous growths that form in the uterus. They are a common condition among women, especially those of reproductive age. These tumors can vary in size, from small growths to large masses that can distort the shape of the uterus. Although many women with uterine fibroids experience no symptoms,
Uterine Manipulator Devices Market Report 2018: Segmentation by Type (Donnez Typ …
Global Uterine Manipulator Devices market research report provides company profile for ConMed, Richard Wolf, Bisinger, Planmeca Oy, Ethicon Endosurgery, Cooper Surgical, Hospiiniz International, C. R. Bard and Others. This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms of volume, revenue, YOY growth rate, and CAGR for the year 2018 to 2025,
Uterine Fibroids Treatment Market : Hysterectomy to Remain Most Preferred Uterin …
The market for uterine fibroids treatment market is fragmented in nature with a high number of players operating in it across the U.S., states a new market research report by Transparency Market Research. The estimated entry of new players and the increasing research and development activities are some of the key factors that are projected to strengthen the competitive scenario of the market throughout the forecast period. The leading players
Uterine Leiomyoma (Uterine Fibroids) - Pipeline Review, H2 2018 - Research By Ma …
Uterine Leiomyoma (Uterine Fibroids) - Pipeline Review, H2 2018, provides an overview of the Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders) pipeline landscape. Uterine Leiomyoma (Uterine Fibroids) - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers
Uterine Fibroids Treatment Market: Rising Prevalence of Uterine Fibroids amongst …
The high prevalence of uterine fibroids across the U.S. has created a significant demand for uterine fibroid treatments across the countries. The growing public concern about the occurrence of uterine fibroids, which are also called uterine leiomyoma, have propelled the demand for treatments and solutions to alleviate the pain, excessive bleeding, and pelvic discomfort. According to the report by Transparency Market Research, the U.S. uterine fibroid treatment market is anticipated to